The power of a unified global network.

Nucleus Network is the only dedicated early-phase clinical trial facility with sites in Australia, the United States and the United Kingdom. Offering a seamless path to First-in-Human and clinical pharmacology success across regions.

When speed, quality, and consistency matter, a fragmented clinical trial model isn’t enough. That’s why Nucleus Network operates under one leadership team, with harmonized SOPs and shared governance across all sites.

Whether you’re running parallel studies or bridging from Australia to the US, our integrated model ensures consistency in data, operations, and regulatory compliance, from start-up to closeout.

Strategic sites built for
Early-Phase success

Nucleus Network - Image

Brisbane,
Australia

  • Centre of Excellence for biosimilars and vaccines
  • Co-located with Royal Brisbane & Women’s Hospital (900-bed)
  • Capacity: 61 beds
Explore Brisbane Facility
Nucleus Network - Image

Melbourne,
Australia

  • Largest early-phase unit in Australia
  • Co-located with The Alfred Hospital (800-bed tertiary facility)
  • Specialist FIH and clinical pharmacology site
  • Capacity: 110 beds
Explore Melbourne Facility
Nucleus Network - Image

Minneapolis,
United States

  • U.S. flagship site with onsite dialysis capabilities
  • Specialization in renal, hepatic, and complex pharmacology
  • Located in the Medical Alley region
  • Capacity: 54 beds
Explore Minneapolis Facility
Nucleus Network - Image

London,
United Kingdom

  • Full service for phase 1 and early phase 2 trials
  • Highly automated on-site laboratory, with rapid turnaround
  • Located in a purpose-designed building, near an NHS hospital
  • Capacity: 145 beds
Explore London Facility

Why our global advantage matters

Global reach, single partner

Sites in Melbourne, Brisbane, Minneapolis, and London are all managed under a single operating structure.

Accelerated start-up

Dual-region capability allows you to start in Australia under the CTN scheme while preparing for U.S. IND activation.

Consistent quality across sites

FDA and EMA-inspected units, shared SOPs, and experienced, cross-trained teams ensure audit-ready delivery.

Tailored trial designs

Flexibility to stage studies by geography, population, or protocol phase, including hybrid SAD/MAD and patient transitions.

Start in Australia. Expand to the U.S. seamlessly.

Sponsors looking to enter the U.S. market can begin First-in-Human dosing in Australia (under the CTN scheme) while preparing an IND in parallel. Once regulatory clearance is received, studies can seamlessly transition to our Minneapolis unit, retaining oversight, quality, and timelines.

  • Access to global patient populations
  • IND de-risking and feasibility support
  • Consistent data sets and site communication
  • Reduced duplication across contracts, training, and systems

One network. Multiple sites. One standard.

From feasibility to first dose, Nucleus Network’s integrated model ensures consistent delivery across every location. Let’s accelerate your early-phase program, without compromise.

Get in touch

Nucleus Network - Image